Drugs / HPP854
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01482013 | Oct 2011 → Mar 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | High Point Pharmaceuticals, LLC. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPP854 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482013 ↗ |
| Route | Oral | “Oral, once a day for 28 days.” NCT01482013 ↗ |